ArticleLeukemia2019

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

Matilde Y Follo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.